PDCD1 and neoplasm: The low PD-L1 expression in human primary osteosarcoma tumors and high PD-L1 expression in metastatic disease neutralize the response of tumor-infiltrating lymphocytes (TILs) effector by interacting with PD-1+, CD8+, and T-cells [36].